Press release
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 million Through 2034: DelveInsight | AstraZeneca, Merck, SpringWorks Therapeutics, Healx, Fosun Pharmaceutical, Pasithea Therapeutics
NF1-PN Market Insights
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034" offers comprehensive epidemiological data along with insights into market trends, an analysis of the competitive landscape, current and emerging therapeutic approaches, and assessments of the patient journey concerning NF1-PN, a rare disease.
The report forecasts that the NF1-PN market across the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, will grow from approximately USD 380 million in 2023 at a considerable CAGR by 2034. This anticipated growth is attributed to ongoing research into the genetic underpinnings of these tumors, the availability of medical therapy as an alternative to surgery, improvements in administration ease, and a decrease in side effect profiles of emerging therapies.
Discover evolving trends in NF1-PN market growth @ https://www.delveinsight.com/report-store/neurofibromatosis-type1-associated-plexiform-neurofibromas-nf-pn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
According to the report, the United States consistently holds the highest market share among the 7MM, with around USD 230 million in 2023.
The report provides a detailed epidemiological analysis and forecasts up to 2034, segmented by total NF1 diagnosed prevalent cases, diagnosed cases of NF1 manifestations, age-specific NF1-PN diagnosed cases, NF1-PN cases by clinical symptoms, and NF1-PN cases eligible for surgery in the 7MM. In 2023, the majority of diagnosed NF1-PN patients were estimated to be in the US, followed by Germany.
Current NF1-PN treatment practices, emerging drugs, market shares of individual therapies, and unmet medical needs from 2020 to 2034 are also addressed in the report. While surgery remains a standard treatment for many patients, it is often complex, not always feasible, carries inherent risks, and has a high possibility of tumor recurrence. A multidisciplinary approach involving genetics, neurology, radiology, and surgery, is vital for effectively managing the disease's physical and emotional impacts.
With an improved understanding of the genetic basis of plexiform neurofibromas, targeted therapies like the MEK inhibitor KOSELUGO (AstraZeneca and Merck) have emerged as promising options, especially for pediatric patients with inoperable NF1-PN. Building on this progress, researchers are exploring other MEK inhibitors for potential use in both pediatric and adult patients.
The current NF1-PN developmental pipeline includes additional MEK inhibitors such as Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Another emerging drug, HLX-1502 (Healx), offers a unique investigational treatment option for NF1 patients. In October 2024, the US FDA granted Fast Track Designation (FTD) to HLX-1502 for the treatment of NF1.
Delve deeper into how companies are navigating this landscape @ https://www.delveinsight.com/report-store/neurofibromatosis-type1-associated-plexiform-neurofibromas-nf-pn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Recent developments include findings for PAS-004, which demonstrated no dose-limiting toxicities in Phase 1 clinical trials. An external Safety Review Committee recommended proceeding with its higher doses without modification in February 2025, highlighting the potential of these emerging therapies to revolutionize NF1-PN treatment.
Discover more recent advancements @ https://www.delveinsight.com/report-store/neurofibromatosis-type1-associated-plexiform-neurofibromas-nf-pn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Although NF1-PN presents significant challenges due to its highly individualized treatment needs-including multidisciplinary teamwork, tumor regrowth, and complications arising from tumors developing in critical areas like the head, neck, chest, or spine-the emergence of novel therapies as an alternative to surgery, improving administration ease and minimize side effects, is expected to broaden treatment options and enhance market growth.
For strategic insights, visit: https://www.delveinsight.com/report-store/neurofibromatosis-type1-associated-plexiform-neurofibromas-nf-pn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Scope of the NF1-PN Market Report:
Study Period: 2020-2034
Coverage: 7MM [US, UK, EU4 (France, Germany, Italy, and Spain), and Japan]
Key NF1-PN Companies
Key NF1-PN Therapies
NF1-PN Therapeutic Assessment
NF1-PN Market Dynamics
Competitive Intelligence Analysis
NF1-PN Unmet Needs, KOL Views, Analyst Views, NF1-PN Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. NF1-PN Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. NF1-PN Background and Overview
8. NF1-PN Treatment
9. NF1-PN Epidemiology and Patient Population in the 7MM
10. NF1-PN Patient Journey
11. NF1-PN Marketed Drug
12. NF1-PN Emerging Drugs
13. NF1-PN: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 million Through 2034: DelveInsight | AstraZeneca, Merck, SpringWorks Therapeutics, Healx, Fosun Pharmaceutical, Pasithea Therapeutics here
News-ID: 4258473 • Views: …
More Releases from DelveInsight Business
Polycythemia Vera Market Set for Significant Growth Across 7MM Driven by Innovat …
The 7MM Polycythemia Vera market size reached approximately USD 1,900 million in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience and Disc Medicine, GluBio Therapeutics, and others are spearheading innovations in treatment approaches, addressing critical unmet needs in managing this…
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Per …
The HER2+ Gastric Cancer market is projected to grow significantly in the 7MM, which includes the United States, EU4-Germany, France, Italy, and Spain-the United Kingdom, and Japan. This growth is attributed to several factors, including the increasing incidence of HER2+ Gastric Cancer, advances in research and development, and innovations in the treatment landscape by various key HER2+ Gastric Cancer companies such as Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo…
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 20 …
The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among healthcare professionals contributing to earlier diagnosis, increasing chronic UV exposure, and the emergence of innovative therapies such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals / AgonOx), KT 253 (Kymera Therapeutics) and others.
DelveInsight's latest report, "Merkel Cell Carcinoma Market Insight, Epidemiology,…
Pompe Disease Market Set for Robust Growth Through 2034, Driven by Breakthrough …
The Pompe disease treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Sanofi, Genzyme, Amicus Therapeutics, GeneCradle Therapeutics, Astellas Gene Therapies, Spark Therapeutics, Aro Biotherapeutics, Maze Therapeutics, Valerion Therapeutics, Actus Therapeutics, Roche, and Lacerta Therapeutics, among others.
DelveInsight's "Pompe Disease Market Insight, Epidemiology And Market Forecast - 2034" report delivers an in-depth understanding of the Pompe disease treatment market,…
More Releases for NF1
Plexiform Neurofibroma Market to Grow at 9.7% CAGR from 2025 to 2034
Subheadline:
Rising research in neurofibromatosis type 1 (NF1), FDA approvals of MEK inhibitors, and emerging gene-editing therapies are driving strong global growth in the plexiform neurofibroma market.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72662
Introduction
The Plexiform Neurofibroma Market is entering a period of rapid expansion as precision medicine and genetic therapies reshape the management of neurofibromatosis type 1 (NF1) and related tumor growth disorders.
Valued at USD 410 million in 2024,…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US.
Key NF1 Market Highlights
*
The Neurofibromatosis Type 1 treatment…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to R …
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often…
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 …
The the emergence of new transformative NF1-PN treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics), and others.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks…
